Breast implant infections: Is cefazolin enough?

Plastic and Reconstructive Surgery

Volumn 126, Issue 3, 2010, Pages 779-785

  Feldman, Evan M ^a   Kontoyiannis, Dimitrios P ^a   Sharabi, Safa E ^a   Lee, Edward ^a   Kaufman, Yoav ^a   Heller, Lior ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFAZOLIN;

ADULT; AGED; ARTICLE; BREAST ENDOPROSTHESIS; FEMALE; HUMAN; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BREAST IMPLANTS; CEFAZOLIN; FEMALE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 77956460979     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181e5f7ff     Document Type: Article

References (20)

1. American Society of Plastic Surgeons. National Clearinghouse of Plastic Surgery Statistics: 2008 report of 2007 statistics. Available at: http://www.plasticsurgery.org/Media/Statistics/ 2007-Statistics.html. Accessed November 1, 2009.
2. Kjøller K, Hölmich LR, Jacobsen PH, et al. Epidemiological investigation of local complications after cosmetic breast implant surgery in Denmark. Ann Plast Surg. 2002;48:229-237.
3. Gabriel SE, Woods JE, O'Fallon WM, Beard CM, Kurland LT, Melton LJ III. Complications leading to surgery after breast implantation. N Engl J Med. 1997;226:677-682.
4. Pittet B, Montandon D, Pittet D. Infection in breast implants. Lancet Infect Dis. 2005;5:94-106.
5. De Cholnoky T. Augmentation mammaplasty: Survey of complications in 10,941 patients by 265 surgeons. Plast Reconstr Surg. 1970;45:573-577.
6. Daum RS. Clinical practice: Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007;357:380-390.
7. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillinresistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-674.
8. St. Luke's Episcopal Hospital Antibiotic Susceptibility Report. Houston, Texas: St. Luke's Episcopal Hospital; July through December 2008. Available at: http://www.plastic surgery.org/Media/Statistics/2007-Statistics.html. Accessed November 1, 2009.
9. Miller TA. Modern Surgical Care. 3rd ed. St. Louis: Quality Medical; 2006:149.
10. Francis SH, Ruberg RL, Stevenson KB, et al. Independent risk factors for infection in tissue expander breast reconstruction. Plast Reconstr Surg. 2009;124:1790-1796.
11. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: Its production and regulation. Int J Artif Organs 2005;28:1062-1068.
12. Curtin J, Cormican M, Fleming G, Keelehan J, Colleran E. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother. 2003;47:3145-3148.
13. Evans RC, Holmes CJ. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother. 1987;31:889-894.
14. Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother. 1990;161:37-40.
15. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother. 1995;39:2397-2400.
16. Wiederhold NP, Coyle EA, Raad II, Prince RA, Lewis RE. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia. J Antimicrob Agents Chemother. 2005;55:792-795.
17. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51: 1656-1660.
18. Garey KW, Dao T, Chen H, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J Antimicrob Chemother. 2006;58:645-650.
19. Luzzati R, Sanna A, Allegranzi B, et al. Pharmacokinetics and tissue penetration of vancomycin in patients undergoing prosthetic mammary surgery. J Antimicrob Chemother. 2000; 45:243-245.
20. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-794.